(Q31027953)

28 June 2017

1 reference

title

Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis (English)

1 reference

28 June 2017

0 references

Rohit Bakshi

1

1 reference

28 June 2017

Venkata S R Dandamudi

2

1 reference

28 June 2017

Mohit Neema

3

1 reference

28 June 2017

Chitradeep De

4

1 reference

28 June 2017

Robert A Bermel

5

1 reference

28 June 2017

language of work or name

1 reference

1 January 2005

1 reference

28 June 2017

Journal of Neuroimaging

1 reference

28 June 2017

15

1 reference

28 June 2017

4 Suppl

1 reference

28 June 2017

30S-45S

1 reference

describes a project that uses

28 June 2017

magnetic resonance imaging

1 reference

based on heuristic

inferred from title

cites work

A Wallerian degeneration pattern in patients at risk for MS.

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Neuronal cell injury precedes brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1051228405283901

21 January 2018

Identifiers

DOI

10.1177/1051228405283901

1 reference

28 June 2017

1 reference